ArticleTranslational cancer research2026
Integrated transcriptomics identifies HIF1A and GSTP1 as biomarkers for cutaneous squamous cell carcinoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous squamous cell carcinoma (cSCC) is one of the most common skin malignancies with limited reliable biomarkers for early detection and prognosis. This study integrated bulk and single‑cell transcriptomic data to identify post‑translational modification-related key genes and to characterise cellular and immune alterations in cSCC. Methods: Publicly available cSCC datasets and post-translational modification-related genes (PTMRGs) were analysed. Single-cell analysis identified key cell populations and differentially expressed genes (DEGs), which were intersected with bulk DEGs, weighted gene co‑expression network modules, and PTMRGs. Candidate genes were prioritised using five feature selection algorithms, validated by quantitative real-time polymerase chain reaction (qRT-PCR) and receiver operating characteristic (ROC) analysis [area under the curve (AUC) >0.7]. Functional exploration included predictive modelling, SHapley Additive Explanations (SHAP) interpretation, immune infiltration analysis, protein interaction mapping, drug prediction with molecular docking, intercellular communication inference, and pseudotime trajectory analysis. Results: Keratinocytes were identified as the key cell population, yielding 999 single-cell-differentially expressed genes (sc-DEGs). Bulk analysis detected 5,771 DEGs and 17 co‑expression modules; intersection yielded 19 candidate genes. Multi‑method feature selection nominated HIF1A, UBC, and GSTP1; validation retained HIF1A and GSTP1 as final diagnostic markers (upregulated in cSCC; AUCs >0.7). A least absolute shrinkage and selection operator (LASSO) classifier achieved the best performance. SHAP highlighted HIF1A and GSTP1 as dominant contributors. HIF1A was predicted to be nuclear, GSTP1 mitochondrial; both correlated positively with macrophages, natural killer (NK) cells, and neutrophils. Drug prediction and docking identified camptothecin, hydroquinone, and resveratrol with favorable binding (e.g., HIF1A-camptothecin -8.7 kcal/mol; GSTP1-camptothecin -8.6 kcal/mol). Cell-cell signaling was enhanced in cSCC [vascular endothelial growth factor (VEGF), endothelin (EDN) pathways; elevated MIF-(CD74+CXCR4) and MIF-(CD74+CD44)]. Keratinocyte pseudotime revealed progression from normal to metastatic states with concordant keratinocyte‑related gene programs. Conclusions: HIF1A and GSTP1 are promising diagnostic biomarkers for cSCC, linked to altered immune landscapes, enhanced intercellular signaling, and potential druggable interactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.